Bosutinib in the management of chronic myelogenous leukemia

References

• CortesJGoldmanJMHughesTCurrent issues in chronic myeloid leukemia: monitoring, resistance, and functional cureJ Natl Compr Canc Netw201210Suppl 3S1S1323055247
   PubMed Web of Science ®Google Scholar
• DeiningerMWO‘BrienSGFordJMDrukerBJPractical management of patients with chronic myeloid leukemia receiving imatinibJ Clin Oncol20032181637164712668652
   PubMed Web of Science ®Google Scholar
• O‘BrienSGGuilhotFGoldmanJMInternational Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM)ASH Annual Meeting Abstracts2008 Abstract 186
   Google Scholar
• SawyersCLHochhausAFeldmanEImatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood200299103530353911986204
   PubMed Web of Science ®Google Scholar
• RowleyJDLetter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa stainingNature197324354052902934126434
   PubMed Web of Science ®Google Scholar
• DeiningerMGuilhotFGoldmanJMInternational Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinibASH Annual Meeting Abstracts2009 Abstract 1126
   Google Scholar
• BuchdungerEZimmermannJMettHInhibition of the Abl protein- tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivativeCancer Res19965611001048548747
   PubMed Web of Science ®Google Scholar
• ErnstTHochhausAChronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progressionSemin Oncol2012391586622289492
   PubMed Web of Science ®Google Scholar
• KantarjianHGilesFWunderleLNilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLN Engl J Med2006354242542255116775235
   PubMed Web of Science ®Google Scholar
• HochhausAKantarjianHMBaccaraniMDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood200710962303230917138817
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHMBrümmendorfTHSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood2011118174567457621865346
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWKantarjianHMBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trialJ Clin Oncol201230283486349222949154
   PubMed Web of Science ®Google Scholar
• SaglioGKimDWIssaragrisilSENESTnd InvestigatorsNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med2010362242251225920525993
   PubMed Web of Science ®Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• Keller-von AmsbergGKoschmiederSProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaOnco- Targets and Therapy20133 Volume 2013699106
   PubMed Web of Science ®Google Scholar
• GoldenbergMMPharmaceutical approval updateP T2012371162064923204815
   PubMedGoogle Scholar
• AbbasRHugBALeisterCBurnsJSonnichsenDEffect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjectsJ Clin Pharmacol201151121721172721148045
   PubMed Web of Science ®Google Scholar
• AbbasRHugBALeisterCGaaloulMEChalonSSonnichsenDA phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjectsCancer Chemother Pharmacol201269122122721691746
   PubMed Web of Science ®Google Scholar
• AbbasRChalonSLeisterCGaaloulMESonnichsenDEvaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjectsCancer Chemother Pharmacol201371112313223053269
   PubMed Web of Science ®Google Scholar
• PuttiniMColucciaAMBoschelliFIn vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr- Abl+ neoplastic cellsCancer Res20066623113141132217114238
   PubMed Web of Science ®Google Scholar
• GolasJMArndtKEtienneCSKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude miceCancer Res200363237538112543790
   PubMed Web of Science ®Google Scholar
• BoschelliDHYeFWangYDOptimization of 4-phenylamino-3- quinolinecarbonitriles as potent inhibitors of Src kinase activityJ Med Chem200144233965397711689083
   PubMed Web of Science ®Google Scholar
• LiSSrc-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemiaLeuk Lymphoma2008491192618203007
   PubMed Web of Science ®Google Scholar
• Remsing RixLLRixUColingeJGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cellsLeukemia200923347748519039322
   PubMed Web of Science ®Google Scholar
• ManciniMBrusaGZuffaEPersistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606Leuk Res200731797998717129604
   PubMed Web of Science ®Google Scholar
• KhouryHJCortesJEKantarjianHMBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood2012119153403341222371878
   PubMed Web of Science ®Google Scholar
• KhouryHJGambacorti-PasseriniCKantarjianHMBosutinib as therapy for chronic phase chronic myeloid leukemia following failure with imatinib plus dasatinib and/or nilotinib: 24-month minimum follow- up updateASH Annual Meeting Abstracts2012 Abstract:3785
   Google Scholar
• CortesJEKhouryHJLiptonJHBaseline predictors of response to bosutinib in patients with chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib plus dasatinib and/or nilotinibASH Annual Meeting Abstracts2012 Abstract:2793
   Google Scholar
• LevinsonNMBoxerSGStructural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domainPLoS One201274e2982822493660
   PubMed Web of Science ®Google Scholar
• RedaelliSPiazzaRRostagnoRActivity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutantsJ Clin Oncol200927346947119075254
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHMKimDWBosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 36-month minimum follow-up updateASH Annual Meeting Abstracts2012 Abstract:3779
   Google Scholar
• BraveMGoodmanVKaminskasESprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylateClin Cancer Res200814235235918223208
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAHanXKantarjianHCortesJTyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemiaBlood2009114226126319414863
   PubMed Web of Science ®Google Scholar
• HsyuPHMouldDRUptonRNAmanteaMPharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemiaCancer Chemother Pharmacol201371120921823070145
   PubMed Web of Science ®Google Scholar
• CortesJLiptonJHReaDOmacetaxine 202 Study GroupPhase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutationBlood2012120132573258022896000
   PubMed Web of Science ®Google Scholar
• HughesTSaglioGBranfordSImpact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseJ Clin Oncol200927254204421019652056
   PubMed Web of Science ®Google Scholar
• SoveriniSColarossiSGnaniAResistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainHaematologica200792340140417339191
   PubMed Web of Science ®Google Scholar
• GontarewiczABalabanovSKellerGSimultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315IBlood200811184355436418268096
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaACortesJHomoharringtonine for the treatment of chronic myelogenous leukemiaExpert Opin Pharmacother2008961029103718377344
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWPinilla-IbarzJThe PACE Study GroupInitial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the t315i mutationASH Annual Meeting Abstracts2011 Abstract:109
   Google Scholar
• O‘HareTEideCADeiningerMWNew Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in checkExpert Opin Investig Drugs2008176865878
   PubMed Web of Science ®Google Scholar
• HuYLiuYPelletierSRequirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemiaNat Genet200436545346115098032
   PubMed Web of Science ®Google Scholar
• BantscheffMEberhardDAbrahamYQuantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNat Biotechnol20072591035104417721511
   PubMed Web of Science ®Google Scholar
• Keller-V AmsbergGBrümmendorfTHNovel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemiaExpert Rev Anticancer Ther20121291121112723098112
   PubMed Web of Science ®Google Scholar
• KonigHHolyoakeTLBhatiaREffective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SK-606Blood200811142329233818056843
   PubMed Web of Science ®Google Scholar
• BartolovicKBalabanovSHartmannUInhibitory effect of imatinib on normal progenitor cells in vitroBlood2004103252352912969987
   PubMed Web of Science ®Google Scholar
• Gora-TyborJRobakTTargeted drugs in chronic myeloid leukemiaCurr Med Chem200815293036305119075651
   PubMed Web of Science ®Google Scholar
• TalpazMShahNPKantarjianHDasatinib in imatinibresistant Philadelphia chromosome-positive leukemiasN Engl J Med2006354242531254116775234
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAKantarjianHO‘BrienSPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol200725253908391417761974
   PubMed Web of Science ®Google Scholar
• LimaLBernal-MizrachiLSaxeDPeripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyondCancer201111761245125221381013
   PubMed Web of Science ®Google Scholar
• MarinDIbrahimARLucasCAssessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsJ Clin Oncol201230323223822067393
   PubMed Web of Science ®Google Scholar
• HanfsteinBMüllerMCHehlmannRSAKK; German CML Study GroupEarly molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Leukemia20122692096210222446502
   PubMed Web of Science ®Google Scholar
• BrümmendorfTHKantarjianHMGambacorti-PasseriniCAssessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA studyASH Annual Meeting Abstracts2012 Abstract:69
   Google Scholar
• HochhausAHughesTPSaglioGOutcome of patients with chronic myeloid leukemia in chronic phase (CML-CP) based on early molecular response and factors associated with early response: 4-year follow-up data from ENESTnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)ASH Annual Meeting Abstracts2012 Abstract:167
   Google Scholar
• SaglioGKantarjianHMShahNEarly response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year dataASH Annual Meeting Abstracts2012 Abstract:1675
   Google Scholar